Biomarkers

Non-HDL Cholesterol

A better total atherogenic burden marker than LDL-C alone

Plain English

Non-HDL cholesterol is total cholesterol minus HDL cholesterol, capturing the cholesterol carried by all atherogenic particles combined: LDL, VLDL, IDL, and Lp(a). Because it includes more of the lipoproteins that contribute to arterial plaque, it is a better predictor of cardiovascular events than LDL-C alone and can be calculated from any standard lipid panel without additional testing.

The Mechanism

Standard lipid panels report total cholesterol, HDL-C, triglycerides, and calculated LDL-C. LDL-C only captures cholesterol in LDL particles. Non-HDL cholesterol is simpler: take total cholesterol, subtract HDL, and you get the cholesterol content of everything that is not HDL. This includes VLDL (very low-density lipoprotein), IDL (intermediate-density lipoprotein), and Lp(a) in addition to LDL, all of which are atherogenic.

VLDL carries triglycerides from the liver to peripheral tissues and is the primary precursor of LDL particles. When triglycerides are elevated, VLDL production increases and VLDL remnants linger in circulation longer, contributing to plaque. These VLDL remnants are atherogenic but are missed entirely by LDL-C calculations. Non-HDL-C captures them.

Multiple large-scale analyses have shown that non-HDL-C predicts cardiovascular events more accurately than LDL-C, particularly in people with metabolic syndrome, diabetes, or high triglycerides, where the LDL-C calculation is least accurate. The American College of Cardiology recognizes non-HDL-C as a primary lipid target alongside LDL-C, and some guidelines now list it as the preferred single marker when ApoB is unavailable.

Why It Matters

When triglycerides are high, non-HDL-C is the number to watch.

If your triglycerides are high, your Friedewald-calculated LDL-C may be systematically underestimating your true atherogenic burden. Non-HDL-C corrects for this by capturing VLDL and remnant particles that LDL-C misses. It is particularly useful for people with metabolic syndrome or anyone whose triglycerides are above 150 mg/dL, where standard LDL-C is least reliable. The non-HDL target for primary prevention is below 130 mg/dL; below 100 mg/dL for high-risk individuals.

Common Misconception

Most people only pay attention to LDL-C because it is the most visible number on a lipid panel. Non-HDL-C is calculated in seconds from the same panel (total cholesterol minus HDL) and is more predictive of cardiovascular events for anyone with elevated triglycerides or metabolic dysfunction. It requires no extra test and no extra cost, yet most clinicians never discuss it.

What a Healthy Range Looks Like

Optimal

<100 mg/dL

Target for high-risk individuals; includes those with diabetes, prior cardiovascular events, or elevated ApoB

Near Optimal

100–130 mg/dL

Primary prevention target for most adults without prior cardiovascular disease

Borderline

130–160 mg/dL

Elevated atherogenic burden; particularly concerning alongside high triglycerides or low HDL

Elevated

>160 mg/dL

High atherogenic burden; warrants investigation of all contributing lipoproteins and metabolic factors

Non-HDL-C targets are 30 mg/dL higher than corresponding LDL-C targets by convention, reflecting the added contribution of VLDL and remnant particles. Calculate yours now: total cholesterol minus HDL from your most recent lab. If you do not know your number, you cannot manage it.

Signs It Is Disrupted

Non-HDL-C above 130 mg/dL alongside triglycerides above 150 mg/dL, indicating metabolic dyslipidemia beyond what LDL-C shows
LDL-C appears normal but total cholesterol is disproportionately high relative to HDL
Metabolic syndrome features: central adiposity, high blood pressure, elevated fasting glucose, low HDL, high triglycerides
Fasting triglycerides consistently above 200 mg/dL, making standard LDL-C calculation unreliable

How to Improve It

→

Reduce refined carbohydrates. High refined carb intake drives VLDL production and elevates triglycerides, raising non-HDL-C primarily through the VLDL and remnant particle channels that LDL-C misses.

→

Zone 2 cardio. Aerobic exercise at 150 or more minutes per week improves triglyceride clearance and lowers VLDL production, directly reducing the non-HDL contribution from VLDL remnants.

→

Increase omega-3 intake. EPA and DHA from fatty fish or supplementation (2-4g/day) reduce triglycerides by 15-30% (Skulas-Ray et al., 2019 AHA Scientific Statement), lowering VLDL output and therefore non-HDL-C.

→

Reduce visceral fat. Visceral fat drives hepatic fat accumulation and VLDL overproduction; fat loss concentrated in the visceral compartment produces the most direct reduction in non-HDL-C.

→

Request ApoB. If non-HDL-C is elevated, ApoB provides the next level of precision by directly counting atherogenic particles rather than estimating their cholesterol content.

3 Things to Remember

Non-HDL cholesterol equals total cholesterol minus HDL and captures all atherogenic lipoproteins including VLDL and Lp(a), making it a more complete atherogenic burden marker than LDL-C alone.

When triglycerides are above 150 mg/dL, the standard LDL-C calculation underestimates atherogenic risk; non-HDL-C is the more reliable number in this scenario.

Primary prevention target is below 130 mg/dL; calculate yours from your existing lab panel by subtracting HDL-C from total cholesterol.

Appears In

→The Lab Work & Biomarkers Protocol →How to Interpret Your Lipid Panel: LDL Particles, ApoB, and What Actually Matters

Protocol

Turn what you've learned into daily practice

Protocol pulls your wearable and nutrition data together into a daily health score, morning brief, and AI coaching. All in one place.

Get started free